Browsing tag:


Patients suffering from the rare neuromuscular disorder Lambert-Eaton myasthenic syndrome have recently received life changing news. On August 27, 2013 the FDA decided to grant Amifampridine Phosphate a Breakthrough Therapy Designation, also known as BTD.  Marketed by BioMarin as the brand name Firdapse, Amifampridine Phosphate offers a crucial new hope for patients enduring this fatal[…]

Read More

Treatments Available for Surge of Alzheimers Cases

The approval of Aricept fifteen years ago was the last time there was anything new to treat the symptoms of Alzheimer’s disease. This lack of research and drug development is unnerving to patients and practitioners alike, with this lethal disease affecting 5.4 million Americans. On June 13, 2013 the BCC posted an alarming research report,[…]

Read More

Alzheimers Disease Is The Fastest Growing Health Threat To Americans

A report issued from the University of Washington in Seattle on March 5, 2013 revealed a startling statistic. The fastest growing health threat to Americans is not cancer or heart disease – it is Alzheimers disease! While this may not have been surprising information to groups like the Alzheimer’s Association, who have been predicting an[…]

Read More

Amifampridine, CAS# 54-96-6, is the first and only approved drug thus far for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome in adults. As a rare autoimmune disease, Lambert-Eaton Myasthenic Syndrome, also called LEMS, is typically caused by autoantibodies to voltage gated calcium channels, leading to a reduction in the amount of acetylcholine released from nerve[…]

Read More

Donepezil, CAS number 120014-06-4, is also marketed under the brand name Aricept, and is used in treatment of Alzheimer’s disease. Patients with dementia have low levels of the brain chemical acetylcholine, which is a crucial chemical for thinking and memory issues. Donepezil improves the patient’s nerve cell functioning by inhibiting the breakdown of acetylcholine. Aricept,[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service